Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The extent of tumor shrinkage correlates with long-term outcome.”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
Rosenbaum, P. R., & Rubin, D. B. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478078 · Cited by 3,082
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Self-citationBennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt231 · Cited by 104
Research works printed but not linked: 19
- Siegel, 2012, Cancer statistics, 2012, CA Cancer J Clin, 62, 10, 10.3322/caac.20138 · DOI · Paper page
- Chiappa, 2009, The management of colorectal liver metastases: expanding the role of hepatic resection in the age of multimodal therapy, Crit Rev Oncol Hematol, 72, 65, 10.1016/j.critrevonc.2008.11.003 · DOI
- Ksienski, 2010, Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC), Ann Surg Oncol, 17, 3085, 10.1245/s10434-010-1304-9 · DOI
- Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 · DOI · Paper page
- Piessevaux, 2013, Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab, J Clin Oncol, 31, 3764, 10.1200/JCO.2012.42.8532 · DOI · Paper page
- Giessen, 2013, Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial, Cancer Sci, 104, 718, 10.1111/cas.12148 · DOI
- Modest, 2013, Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial, Acta Oncol, 52, 956, 10.3109/0284186X.2012.752580 · DOI
- Suzuki, 2012, The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy, Ann Oncol, 23, 948, 10.1093/annonc/mdr350 · DOI
- Douillard, 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study, J Clin Oncol, 28, 4697, 10.1200/JCO.2009.27.4860 · DOI · Paper page
- Douillard, 2014, Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer, Ann Oncol, 25, 1346, 10.1093/annonc/mdu141 · DOI · Paper page
- Rosenbaum, 1983, The central role of the propensity score in observational studies for causal effects, Biometrika, 70, 41, 10.1093/biomet/70.1.41 · DOI · Paper page
- Heinemann, 2014, Independent radiological evaluation of objective response, early tumour shrinkage, and depth of response in FIRE-3 (AIO KRK-0306), Ann Oncol, 25, ii117, 10.1093/annonc/mdu193.30 · DOI
- Mansmann, 2012, Improved early prediction of individual prognosis for patients with mCRC: Joint modelling of tumor shrinkage with volume data for PFS and OS, J Clin Oncol, 30
- Mansmann, 2012, Deepness of response: a quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC, J Clin Oncol, 30
- Grothey, 2008, Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107, J Clin Oncol, 26, 183, 10.1200/JCO.2007.13.8099 · DOI · Paper page
- Douillard JY, Peeters M, Rong A et al. Effect of post-protocol anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) therapy on survival outcomes in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) treated with panitumumab (pmab) plus chemotherapy. In: 14th World Congress on Gastrointestinal Cancer; 12 Jun 27; 2012. · doi:10.1016/s0923-7534(20)33181-1
- Omurlu, 2009, Comparison of Bayesian survival analysis and Cox regression analysis in simulated and breast cancer data sets, Expert Syst Appl, 36, 11341, 10.1016/j.eswa.2009.03.058 · doi:10.1016/j.eswa.2009.03.058
- Stein, 2013, Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 Trial, Eur Urol, 64, 994, 10.1016/j.eururo.2012.11.032 · DOI
- Sullivan, 2013, The imaging viewpoint: how imaging affects determination of progression-free survival, Clin Cancer Res, 19, 2621, 10.1158/1078-0432.CCR-12-2936 · DOI
Cited by
Stintzing, S., Modest, D. P., Rossius, L., Lerch, M. M., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30269-8 · Cited by 420
Tomasello, G., Petrelli, F., Ghidini, M., Russo, A., Passalacqua, R., & Barni, S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0278 · Cited by 204
Leto, S. M., Ferri, M., Sassi, F., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 30
Metadata
- Authors
- Douillard, J.-Y., Siena, S., Peeters, M., Koukakis, R., Terwey, J.-H., & Tabernero, J.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 51
- Issue
- 10
- Pages
- 1231-1242
- ISSN
- 0959-8049
- Cited by
- 67
- References
- 4
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.